nw-301
Cell therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2024 (NCT06478251)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- RASImmunity, passive
RAS immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06956261 | Phase 1 | May 10, 2025 | Peking University |
| NCT06484556 | Phase 1 | Jun 19, 2024 | Huazhong University of Science and Technology, Neowise Biotechnology |
| NCT06484790 | Phase 1 | Apr 8, 2024 | Neowise Biotechnology, Tianjin Medical University |
| NCT06478251 | Phase 1 | Mar 31, 2024 | Neowise Biotechnology, Zhejiang University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neowise Biotechnology | For profit | 3 | 0 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1